Has the targeted drug lorlatinib been included in medical insurance?

Lorlatinib is a targeted drug used to treat ALK (tyrosine kinase)-positive non-small cell lung cancer (NSCLC). ALK is a fusion gene, and its abnormal activation is closely related to the development and growth of lung cancer. Lorlatinib is a third-generation ALK inhibitor that has broader inhibitory effects than earlier drugs and can combat some drug-resistant mutants.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. Please consult the local hospital pharmacy for details. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

This drug exhibits remarkable characteristics in its unique chemical structure and mechanism of action. Not only can it cross the blood-brain barrier and effectively inhibit the growth of brain metastases, but it also provides a new treatment option for patients who still develop resistance after treatment with other ALK inhibitors. The development of this anti-cancer drug marks an important advance in the treatment of lung cancer and brings hope to those suffering from ALK-positive non-small cell lung cancer.

Clinical trial results show that lorlatinib shows significant efficacy in the treatment of ALKpositiveNSCLC patients. After the patient received drug treatment, the tumor burden was effectively controlled, and the side effects of the drug were relatively controllable. However, like all drugs, lorlatinib may cause some adverse reactions, including but not limited to nausea, fatigue, headache, etc. Therefore, when using this drug, doctors need to develop an individualized treatment plan based on the patient's specific conditions.